Suvizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | HIV-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
 | This article provides insufficient context for those unfamiliar with the subject. (April 2021) |
Suvizumab is an antiviral and immunomodulator. It binds to HIV-1.[1][2]
References
- ^ "Proposed List number 102 of International Nonproprietary Names" (PDF). WHO Drug Information. 23 (4). Geneva: World Health Organization: 344. 2009. ISSN 1010-9609.
- ^ Kerpan I, Walzem F, Kilsen R. Mikrobiologi III: immunsystem (in Swedish). Cambridge Stanford Books.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |